Larvol Delta

vanucizumab (RG7221) - Roche

Roche: Q1 FY 2016 Results (Roche) - Apr 23, 2016 - Anticipated NME submission in US for CRC in 2019 or later; Anticipated submission in EU for CRC in 2019 or later
Anticipated BLA • Anticipated EU regulatory • Colorectal Cancer • Oncology

http://www.roche.com/irp1q16e.pdf

Apr 23, 2016